Avner Avissara

• Enzymotec Australia
• Enzymotec Singapore
• Advanced Lipids Sweden
• Teva Israel- member of the board
• Valpharma France – which has an active subsidiary in Romania
• Valmedica Romania
• South Africa –Director in four of Teva's South African companies
• Teva SA Pty
• Pharmachemie Pty
• Denkavit SA Pty
• Med Ilac Turkey -Teva Turkey.

(Following the acquisition of Dupont Nutrition & Bioscience )

• Member of board of the Joint Venture Advanced Lipids
• Manage All Health Segments Business development
• Lead strategy & Execution of Dietary Supplement segment, Early Life Nutrition Segment, Medical Nutrition Segment, Food & Beverage Segment, Sports & Active life Nutrition segment, Medical Nutrition segment
• All valuated at 700 MM USD.

(Following the acquisition of Frutarom by IFF)

• Developed and implemented go-to market strategy
• Managed relations with JV partner
• Headed ASPAC sales teams’ organizations
• Responsible for strategy and its implementation
• Managed relevant P&L’s

(Following the acquisition of Enzymotec by Frutarom)

• Developed go-to market strategy and oversaw its implementation
• Managed relations with JV partner
• Managed global team- over 26 employees
• Managed innovation portfolio
• Worked closely with sales managers in various territories
• Optimized sales force organization
• Built customers support system

• Overall responsibility for commercial activities of the company
• Managed global activity of Infant Nutrition – Current products and R&D portfolio
• Managed Premium Dietary Supplement Omega 3 product- Krill oil – generating fierce pressure on global leading competitor
• Led divestment of Premium Omega 3 Business – (sold to leading global competitor for 21.6 M USD)
• Managed global Cognitive product with variety of clinically validated indications
• Led due diligence in Infant Nutrition markets, aiming to enter JV's and possible acquisitions
• Managed clinical marketing team, generating innovative marketing approaches to various markets
• Participated in dozens of new products launches
• Generated strong connection within the Infant Formula industry
• Generated 78% growth in 2017, leveraging regulation changes to company’s benefit
• Specialized in China market, Australia, NZ and Europe
• Supported introduction of an innovative portfolio

• Designed strategy for Infant Nutrition Business
• Led reorganization of sales organization
• Opened offices in China Singapore and Australia expanding sales organization
• Built dedicated global sales force for infant nutrition covering all manufacturers, OEM's and Infant Brands
• Designed and implemented go-to market strategy of Infat product
• Managed partnerships with JV partners
• Managed sales organization, set working procedures.
• Implemented unique marketing approach, helping B2B customers offer value to their B2C customers
• Positioned Advanced Lipids as a leading global supplier
• Implemented digital marketing into China, managing PR's, participating in all global exhibitions and conferences.
• Developed and managed relations with key figures in the Infant Formula market
• Led the development of a Human Milk Research center, and a KOL forum to manage innovation
• Managed clinical marketing team leveraging science translating it to marketing and consumer messages.
• Signed strategic agreements with key customers

• Managed Dietary Supplements sales to Australia & New Zealand
• Built infrastructure for Supplements sales in China

• Introduced Israeli companies to new markets.
• Supported business development and commercial approach design for new businesses.
• Initiated feasibility studies and Business plan preparation for new initiatives.
• Marketing approach consultancy and implementation of penetration strategies for new businesses.

• Fully responsible for sales organizations and business development in Russia, Ukraine,
  Turkey, Kazakhstan Central Asia and Africa.
• Responsible for development of business through acquisitions and new products developments.
• Led implementation of new technologies and leading innovation in the markets with a global R&D team.
• Expanded business activities through different marketing models.
  
  

• Managed a special project in “Global Generics penetration” to support the Japanese government
• Special marketing project in Chinese Interferon market.

• Full responsibility for integration process of Barr / Pliva acquisition in the region.
• Led integration of two organizations with over 110 employees into one company.

• Full responsibility for an ever-growing organization of 155 employees in Turkey and over all of Teva's businesses and organizations in Africa (South Africa & Kenya),Cyprus and Malta
• Led integration and finalized acquisition of Med Ilac Turkey
• Managed organizational changes while retaining talent and cultivating growth of the company (39% growth in 2007, $43M turnover 2008)
• Member of board of directors
• Responsible for strategic planning and execution of business plans, implementation of new business development projects and increasing organizational efficiency
• Managed Generic portfolio from R&D stage to launch through local regulatory processes
• Managed supply chain projects – transitioning from in-house services to third party logistics (annual savings of $0.5M)
• Led negotiations with governmental authorities, wholesalers and industry leaders
• Member of Teva Israel executive management.

• Managed Sales & Marketing activities in Turkey, Slovenia, Croatia, Serbia, Macedonia, Albania, Africa, Cyprus and Malta
• Responsible and accountable for P&Ls in these countries
• Led integration of Ivax in all countries
• Prepared infrastructure for Teva’s future growth in the markets, through strategic planning, and implementation of business plans
• Member of Teva CEE Board and Teva International Board

• Responsible for all Teva’s S&M activities in Turkey, Romania, Bulgaria, Slovenia, Croatia, Serbia & Montenegro, Macedonia, Albania, Cyprus, Malta and Africa; Increasing the regional activity from $18M to $36M.
• Initiated Teva’s activities in Bulgaria- starting from 3rd party relations to the establishment of Teva's local representative office, becoming a limited company and acquiring the local partner.
• Developed Romanian business from $3M turnover to $15M in 4 years moving from 3rd party relations into own subsidiary.
• Managed complicated distribution agreements with exit formulas, engaging multi-national auditing companies

• Responsible for initiating Teva’s activities in Turkey, Romania, Bulgaria, Slovenia, Croatia, Serbia, Macedonia, Albania, Cyprus, Malta, Africa and Middle East countries. Grew sales from $9M to $18M in 3 years.
• Managed business development strategy & implementation, from thorough market analysis to full presentation of business plan, taking into consideration: local macro-economical data, political situations, ethnic sensitivities, business environment, business culture, healthcare market analysis, current and future trends analysis, local Pharma-analysis and opportunity analysis.
• Responsible for selection of distributors and design of the right legal partnerships /alliances.

• Responsible for the marketing of various product lines such as Antiseptics, TPN – Total Parenteral & Enteral Nutrition
• Designed marketing strategy, maintained relations with key opinion leaders, organized exhibitions, participated in international forums and round tables
• Prepared promotional material & supported sales force.

• Lundbeck
• Managed Lundbeck Denmark Psychiatry line
• Launched new line of Antipsychotic drugs
• Developed contacts within the Israeli Psychiatry Society, managed professional training of medical representatives and doctors
• Became one of Lunbeck International Marketing Strategy Planners